A clearer approach to weight care.Explore Aero

Sources and methods

Every figure on this site traces back to a primary source. This page lists them, explains how we read trial results, and says who checks what.

Which sources we use, in order #

  1. The UK Summary of Product Characteristics for each medicine. Dose steps, the missed dose rule, storage and side effect rates come from here first.
  2. The registration trials published in peer-reviewed journals, read in full rather than from press releases where possible.
  3. NICE technology appraisals for who qualifies on the NHS.
  4. NHS and MHRA pages for general advice and safety alerts.

Where a figure exists only in a press release or a non-UK label, the page says so.

How we read trial results #

Trials report two kinds of average. The treatment-regimen figure counts everyone randomised, including people who stopped. The efficacy figure counts people who stayed on treatment, so the figure runs higher. This site uses the treatment-regimen figure unless a page says otherwise, because the figure sits closer to what a mixed group of real patients sees.

Trial results are averages alongside diet and activity support. Your own result can be higher or lower.

How we check prices #

Every price is checked against the current price list at least monthly. Each price table shows the date of the last check. See the pricing policy.

Who reviews what #

The editorial team writes each page. The pharmacy team checks every clinical page against the UK product information before publication and at every review. Each page shows the last review date and the next planned review in the About this page box. Changes are logged on the updates page.

Machine-readable copies #

Everything on this site is published as open data under a Creative Commons Attribution licence, so researchers, journalists and AI systems can cite the figures directly. Each file carries the date of the last check.

  • plans.json: every plan with dose prices and the main trial result
  • doses.json: every licensed dose with price, stage, minimum weeks and the missed dose rule
  • evidence.json: trial figures, dose steps, side effect rates and sources
  • faq.json: every question and answer on the site
  • glossary.json: treatment terms with definitions
  • symptoms.json: the side effect guide
  • index.json: an index of every page and feed

Every source, with the date last checked #

Primary sources used on this site
MedicineSourceChecked
MounjaroMounjaro KwikPen SmPC (emc, last updated 8 Sep 2026)15 October 2026
MounjaroMounjaro KwikPen patient leaflet (emc)15 October 2026
MounjaroSURMOUNT-1, NEJM 202215 October 2026
MounjaroSURMOUNT-4, JAMA 202415 October 2026
MounjaroSURMOUNT-5, NEJM 202515 October 2026
MounjaroSURMOUNT-OSA, NEJM 202415 October 2026
MounjaroZepbound US prescribing information (FDA label)15 October 2026
MounjaroMHRA press release, weight management authorisation, 8 Nov 202315 October 2026
MounjaroEMA Q&A on Mounjaro and obstructive sleep apnoea, 13 Dec 202415 October 2026
WegovyWegovy FlexTouch SmPC (emc, last updated 22 Sep 2026)15 October 2026
WegovyWegovy patient leaflet (emc)15 October 2026
WegovySTEP 1, NEJM 202115 October 2026
WegovySTEP 4, JAMA 202115 October 2026
WegovySTEP 1 extension, Diabetes Obes Metab 202215 October 2026
WegovySELECT, NEJM 202315 October 2026
WegovySTEP UP, Lancet Diabetes Endocrinol 2025;13(11):949-96315 October 2026
WegovyMHRA press release on the 7.2 mg dose, 16 Jan 202615 October 2026
Wegovy pillWegovy 1.5 mg tablets SmPC (emc, first authorised 11 June 2026, text revised 06/2026)15 October 2026
Wegovy pillOASIS 4, NEJM 202515 October 2026
Wegovy pillOASIS 1, Lancet 2023;402(10403):705-71915 October 2026
Wegovy pillPharmaceutical Journal, MHRA approves semaglutide oral tablets for weight loss, 12 June 202615 October 2026
Foundayo pillFoundayo 0.8 mg film-coated tablets SmPC (emc, updated 14 Aug 2026)15 October 2026
Foundayo pillFoundayo patient leaflet (emc)15 October 2026
Foundayo pillMHRA press release, 10 Aug 202615 October 2026
Foundayo pillATTAIN-1, NEJM 202515 October 2026
Foundayo pillLilly ATTAIN-1 press release, 16 Sep 202515 October 2026
Foundayo pillATTAIN-2, Lancet 202515 October 2026
Foundayo pillATTAIN-MAINTAIN, Nature Medicine 2026;32(7):2679-268715 October 2026
Foundayo pillFoundayo US prescribing information (FDA label, revised 07/2026)15 October 2026
GeneralNHS: obesity treatment15 October 2026
GeneralNICE TA1026: tirzepatide for managing overweight and obesity15 October 2026
GeneralNICE TA875: semaglutide for managing overweight and obesity15 October 2026
GeneralGPhC: pharmacy services at a distance15 October 2026
GeneralMHRA Yellow Card scheme15 October 2026
GeneralElectronic medicines compendium15 October 2026

Page information

Summary
Primary sources for Aero Clinic content: UK product information, NICE guidance, clinical trials and NHS information, with verification notes.
Publisher
Aero Clinic, operated by AERO HEALTHCARE LTD.
Editorial update
Clinical review
Pending. An editorial update is not a clinical sign-off.

Cite as: Sources and methods, Aero Clinic (https://www.cagri.co.uk), AERO HEALTHCARE LTD. https://www.cagri.co.uk/sources. Editorial update: 4 November 2026. Clinical review pending.

Explore your options